Indications
Tivdak as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy (see section 5.1).
Composition
- Active substance
- tisotumab vedotin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Tivdak
- Active substance
- tisotumab vedotin
- ATC code
- L01FX23
- Therapeutic area
- Uterine Cervical Neoplasms
- Marketing authorisation holder
- Genmab A/S
- Status
- Authorised